The risk aversion selloff continued as the Trump administration's move to escalate its trade war with other countries further shook already fragile risk sentiment in global financial markets. Investors feared U.S. President Donald Trump's shock move to slap tariffs on Mexico risked tipping the United States, and maybe the whole world, into recession.Washington will impose a 5per cent tariff from June 10, which would then rise steadily to 25per cent until illegal immigration across the southern border was stopped.
The declines was also fueled after China's manufacturing purchasing managers' index (PMI) -- a gauge of sentiment among factory operators -- disappointed for May, questioning the effectiveness of Beijing's stimulus steps. China's official manufacturing PMI for May fell into contraction territory. April's reading was 50.1, which was only marginally above the threshold for expansion, but May's reading was 49.4, which suggests that manufacturing activity in May actually shrank. The most eye-catching sub-index is the "new orders index", which measures domestic manufacturing activity. This came down drastically from 51.4 in April to 49.8 in May. PMI readings above 50 indicate expansion, while those below that signal contraction.
The official PMI survey typically polls a large proportion of big businesses and state-owned enterprises. A separate survey, the Caixin indicator, features a bigger mix of small- and medium-sized firms. The Caixin manufacturing PMI is due on June 3.
The ongoing trade fight between the U.S. and China also continues to weigh on markets, following a recent escalation in rhetoric. Chinese vice Foreign Minister Zhang Hanhui said Thursday that provoking trade disputes amounted to naked economic terrorism. Also, China has reportedly halted soy purchases from the U.S.
Shares of property developers were lower. Wharf Real Estate Investment (1997 HK) was down 4.64% at HK$53.50; Sun Hung Kai Properties slid 4.4% to HK$124; Henderson Land was down 3.45% at $40.55.
IPO debutant biopharmaceutical company Mabpharm (2181 HK) closed lower than its HK$1.5 offer price, finishing at HK$1.21.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
